Characteristics of the study (our new findings) that evaluated the association between genome-wide DNA methylation patterns measured in breast cancer tissues and response to targeted treatment in HER2-positive, trastuzumab-treated breast cancer patients are presented in Supplementary Table 3. The gene discussed is ERBB2; the disease is breast carcinoma.